Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

The extension brings a $10 million fee while preserving Nurix’s options to share U.S. economics on up to two programs.

Rhea-AI Summary

Nurix Therapeutics (NRIX) and Gilead Sciences agreed to a second two-year research term extension for an undisclosed oncology program.

Nurix will receive a $10 million extension fee under the amended collaboration agreement, originally established in 2019. Gilead has an option to license resulting drug candidates. Nurix retains options for 50/50 U.S. profit and loss sharing on up to two programs, subject to restrictions. Exercising an option also entails sharing U.S. development costs and receiving reduced milestone payments, with royalties on sales outside the United States.

As of May 31, 2026, Nurix is eligible for up to approximately $1.3 billion in total payments tied to additional fees, payments and successful milestones. It is also eligible for tiered sales royalties. GS-6791 (NX-0479), the first program licensed by Gilead under the agreement, is now in Phase 1 clinical development.

6 points · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointResearch term extension adds two years for the undisclosed oncology program with Gilead.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Extension fee will provide Nurix with $10 million under the amended agreement.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Payment eligibility totals up to approximately $1.3 billion as of May 31, 2026, subject to fees and successful milestones. 54% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.Retained options offer 50/50 U.S. profit sharing and co-development on up to two programs.
• Minor point. Forward-looking: it has not happened yet and may not happen.Royalty eligibility covers mid-single-digit to low-teens percentage tiered royalties on annual net sales from commercial products.
• Minor pointGS-6791 (NX-0479), discovered by Nurix and licensed by Gilead, is now in Phase 1 clinical development.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Exercised program options require 50/50 sharing of U.S. development costs and losses and reduced milestone payments.
• Minor pointNurix’s options on up to two U.S. programs remain subject to certain restrictions.

Key Figures

Research-term extension: 2 years Extension fee: $10 million Potential total payments: Up to approximately $1.3 billion +2 more

Research-term extension

2 years

Additional extension for an oncology program under the Gilead collaboration

Extension fee

$10 million

Fee Nurix will receive under the amended collaboration agreement

Potential total payments

Up to approximately $1.3 billion

Eligible amount as of May 31, 2026, subject to fees, payments, and milestones

U.S. profit-and-loss sharing

50/50 on up to two programs

Nurix options under the collaboration, subject to restrictions

Tiered royalties

Mid-single-digit to low-teens percentage

Annual net sales from commercial products

Key Terms

targeted protein degradation, e3 ligases, irak4 degrader, co-detailing

4 terms

targeted protein degradation technical

"the potential of Nurix’s targeted protein degradation platform"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

e3 ligases technical

"use E3 ligases to induce degradation of specified drug targets"

E3 ligases are enzymes that attach ubiquitin, a small regulatory protein, to specific target proteins; they act as the specificity component of the ubiquitination system by recognizing the protein to be modified and catalyzing transfer of ubiquitin carried by an E2 enzyme. Ubiquitination by an E3 can mark a protein for destruction by the proteasome or alter its activity, location, or interactions, and different E3s recognize different substrates so they determine which cellular proteins are regulated by ubiquitin. A key limitation is that E3s do not act alone: their activity depends on upstream E1 and E2 enzymes and on the presence of appropriate recognition motifs on target proteins, so an E3’s effect requires the full ubiquitin-conjugation apparatus and a compatible substrate.

irak4 degrader medical

"an oral IRAK4 degrader discovered by Nurix"

An IRAK4 degrader is a therapeutic molecule designed to remove the IRAK4 protein inside cells, effectively sending that protein to the cell’s disposal system rather than merely blocking its activity. Investors should care because IRAK4 plays a key role in immune and inflammatory signaling, so degraders offer a different approach to treating autoimmune diseases and certain cancers and can change a drug’s effectiveness, safety profile, and commercial potential compared with traditional inhibitors — like choosing to remove a troublemaker from a room rather than just quieting them.

co-detailing financial

"development, commercialization, and co-detailing on up to two programs"

Co-detailing is a sales practice in which representatives from two different pharmaceutical or medical-product companies jointly visit the same healthcare provider and present information about each company’s product(s) during the same call. It typically involves a pre-arranged agreement about which rep leads parts of the conversation, what materials are used, and how time and responsibilities are shared; it is distinct from formal co-promotion or licensing arrangements because each company retains separate product responsibility and regulatory obligations. Because two companies’ representatives are speaking in the same encounter, co-detailing requires clear coordination of promotional content, disclosure to the provider, and compliance with applicable advertising and promotional rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Two-year extension builds on productive relationship established in 2019

Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States

BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Nurix and Gilead Sciences have agreed to extend the research term for an undisclosed oncology program within the companies’ ongoing strategic collaboration by an additional two years. This is the second two-year extension of the research term for this program.  

“Gilead’s decision to extend the research term for this program reflects our longstanding commitment to productive collaborations, the outstanding dedication of our research teams, and the potential of Nurix’s targeted protein degradation platform to generate novel medicines against therapeutically important targets,” said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. “Our collaboration has already advanced GS-6791, an oral IRAK4 degrader discovered by Nurix, into clinical development, and we are pleased to continue working with Gilead to discover and advance additional drug candidates across oncology and inflammatory diseases. This extension provides further evidence of the value of the collaboration and the capabilities of our platform.”

Under the collaboration agreement, originally established in 2019, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Gilead has an option to license drug candidates resulting from the collaboration, and Nurix retains options for 50/50 profit and loss sharing for development, commercialization, and co-detailing on up to two programs in the United States, subject to certain restrictions. For programs in which Nurix exercises its option, the parties will share U.S. development costs as well as profits and losses 50/50, and Nurix will be eligible to receive royalties on ex-U.S. sales and reduced milestone payments.

In connection with today’s announcement, Nurix will receive a $10 million research term extension fee under the amended collaboration agreement. As of May 31, 2026, Nurix is eligible to receive up to approximately $1.3 billion in total payments based on certain additional fees, payments and the successful completion of certain preclinical, clinical, development and sales milestones. Nurix is also eligible to receive mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. The first program licensed by Gilead under this agreement, GS-6791 (NX-0479), is a potent, selective, oral IRAK4 degrader which is now in Phase 1 clinical development.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and clinical-stage degraders of IRAK4 in collaboration with Gilead and STAT6 in collaboration with Sanofi. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit www.nurixtx.com.

Forward-Looking Statements
This press release contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that reflect Nurix’s expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding: Nurix’s expectations for its collaboration with Gilead Sciences; the potential benefits of Nurix’s collaboration with Gilead Sciences; the potential benefits of the research term extension for the undisclosed oncology program; the potential achievement of milestone, royalty and license payments; and the potential advantages of Nurix’s scientific approach and DEL-AI platform. Forward-looking statements reflect Nurix’s current beliefs, expectations, and assumptions. Although Nurix believes such expectations and assumptions are reasonable, Nurix can give no assurance that they will prove to be correct. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and changes in circumstances that are difficult to predict, which could cause Nurix’s actual activities and results to differ materially from those expressed in any forward-looking statement. Such risks and uncertainties include, but are not limited to: (i) the ability of each party to perform its obligations under the Nurix-Gilead collaboration; (ii) whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Nurix-Gilead collaboration; (iii) the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development; (iv) whether Nurix will be able to fund development activities and achieve development goals, including those under the Nurix-Gilead collaboration; (v) risks and uncertainties relating to the timing and receipt of payments from Nurix’s collaboration partners, including milestone payments and royalties on future potential product sales; and (vi) other risks and uncertainties described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2026, and other SEC filings. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Nurix on its website or otherwise. Nurix disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law.

Contacts:
Media and Investors
Kris Fortner
Nurix Therapeutics, Inc.
ir@nurixtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Nurix’s oncology research extension with Gilead?

The companies agreed to a second two-year extension of the research term for an undisclosed oncology program. Nurix will receive a $10 million research term extension fee under the amended collaboration agreement.

What stage has Nurix’s Gilead-licensed GS-6791 program reached?

GS-6791 (NX-0479) is now in Phase 1 clinical development. It is an oral IRAK4 degrader discovered by Nurix and the first program licensed by Gilead under the collaboration agreement.

What royalties is Nurix eligible to receive under the Gilead collaboration?

Nurix is eligible for mid-single-digit to low-teens percentage tiered royalties on annual net sales from any commercial products. For programs where Nurix exercises its U.S. sharing option, it is eligible for royalties on sales outside the United States and reduced milestone payments.